Sweden, June 2, 2022 /PRNewswire/
-- Immunovia today announced that Philipp Mathieu has been named Chief Executive
Officer and President effective immediately. Since January, Philipp
has been acting Chief Executive Officer and President.
Commenting on the announcement, Carl Borrebaeck, Chairman,
states: "After carefully evaluating external candidates, the board
has decided that Philipp with his extensive financial background
and experience is the right person to lead Immunovia through the
transition from a research-focused company to a successful
commercial enterprise. While serving as acting Chief Executive
Officer and President, Philipp demonstrated effective leadership
and rapidly advanced the company's strategic priorities. Immunovia
is now well positioned for the commercial roll-out of the early
detection of pancreatic cancer with its pioneering IMMray™
PanCan-d test in the US."
"I am honored and excited to continue leading our outstanding
team through this important phase of Immunovia's evolution.
Immunovia is at the forefront of revolutionizing the early
detection of pancreatic cancer and addressing a huge unmet medical
need which is a tremendously motivating mission," says Philipp Mathieu, CEO and President of
Philipp Mathieu has extensive
experience as an adviser on corporate strategy, M&A and capital
markets transactions to healthcare and life sciences companies.
Most recently, Philipp was a Portfolio Manager and Advisor to a
multinational family office. Previously, he was an investment
banker focused in the Healthcare sector at Lazard and Lehman
For more information, please contact:
CEO and President
Senior Director Investor Relations and Corporate Communications
Tel: +46 736 36 35 74
This is information that Immunovia is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact person
set out above, at 08:30 CET
June 2, 2022.
Immunovia AB is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available specifically for the early detection of
pancreatic cancer. The test has unmatched clinical performance.
Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated value of more than USD 4
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
The following files are available for download:
SOURCE Immunovia AB